Investor Area

News

Announcements by type

  • Presentation

  • Corporate

  • Newsletter

  • Regulatory

  • Financial

  • Clinical

  • Reset

 
Tuesday, 03 September 2019

Appendix 3Y

  Change of Director’s Interest Notice Appendix 3Y    

Download PDF
 
 

  Download Notification of Dividend/Distribution

Download PDF
 
 
Wednesday, 28 August 2019

CLINUVEL Clarifies ex-Dividend Date

  In relation to the dividend announcement earlier today, CLINUVEL PHARMACEUTICALS LTD clarifies the ex-dividend date is to be 04 September 2019. Download PDF

Download PDF
 
 
Wednesday, 28 August 2019

CLINUVEL Declares Final Dividend

  CLINUVEL PHARMACEUTICALS LTD is pleased to announce that it will issue a dividend for the financial year ended 30 June 2019. This is the second final dividend in its corporate history. […] Download PDF

Download PDF
 
 

  CLINUVEL PHARMACEUTICALS LTD (CLINUVEL), a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4E and Preliminary Financial Report for the year ending 30 June 2019. […] Download PDF

Download PDF
 
 

  CLINUVEL PHARMACEUTICALS LTD today announced that its program in systemic photoprotection will be discussed and presented at the first European-American meeting of the International Congress on Photobiology and Congress of the European Society for Photobiology, Light and Life, held in Barcelona, Spain, from 25-30 August. […] Download PDF

Download PDF
 
 
Tuesday, 20 August 2019

CLINUVEL Newsletter – August 2019

  Dear patients, shareholders, friends, In this News Communiqué VI for the year we report further on CLINUVEL’s regulatory progress in the US and the latest quarterly results for the period ending 30 June 2019. […] Download PDF

Download PDF
 
 
Wednesday, 31 July 2019

Appendix 4C

  CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow Report for the period 01 April to 30 June 2019.   Download PDF

Download PDF
 
 

  CLINUVEL PHARMACEUTICALS LTD today announced that non-executive Director, Willem Blijdorp has replaced Managing Director and Chief Executive Officer, Dr Philippe Wolgen as a member of the Audit & Risk Committee. […] Download PDF

Download PDF
 
 
Thursday, 11 July 2019

CLINUVEL Newsletter – July 2019

  In this Communiqué we turn our attention to the most recent news communicated to the Company on 31 May by the US Food and Drug Administration (FDA): an extension of the scientific review time for SCENESSE® (afamelanotide 16mg) by three months […] Download PDF

Download PDF
 
 

   21 June 2019      Download PDF

Download PDF
 
 

CLINUVEL INCLUDED IN S&P/ASX 200 INDEX 14 June 2019 Download PDF    

Download PDF
 
 

6 June 2019   Download PDF

Download PDF
 
 

Melbourne, Australia 5 June 2019 Download PDF

Download PDF
 
 

Melbourne, Australia 3 June 2019 Download PDF The FDA sets new goal date of 6 October 2019 to complete review and issue risk-benefit decision CLINUVEL PHARMACEUTICALS LTD today published that the US Food and Drug Administration (FDA) Division of Dermatology and Dental Products (DDDP) has set a new Prescription Drug User Fee Act (PDUFA) goal […]

Download PDF
 

  CLINUVEL PHARMACEUTICALS LTD today announced that Mr Stan McLiesh will retire from his role as Non-Executive Director and Chair of the Board on 30 November 2019. Non-Executive Director Mr Willem Blijdorp has been elected Chair …

Download PDF
 
Thursday, 17 October 2019

CLINUVEL Newsletter

  In this News Communiqué VII, we pause to reflect on the outstanding US regulatory outcome and look back one last time at all the events which led to the long-desired outcome on 8 October, the …

Download PDF
 
Tuesday, 15 October 2019

Chair Letter to Shareholders

  Dear All, In my career in life sciences, I have served on public Boards, was part of the management team that led CSL to its position and oversaw several executive transitions in our beloved Company, first …

Download PDF
 
Tuesday, 20 August 2019

CLINUVEL Newsletter - August 2019

  Dear patients, shareholders, friends, In this News Communiqué VI for the year we report further on CLINUVEL’s regulatory progress in the US and the latest quarterly results for the period ending 30 June 2019. [...]

Download PDF
 
Thursday, 11 July 2019

CLINUVEL Newsletter - July 2019

  In this Communiqué we turn our attention to the most recent news communicated to the Company on 31 May by the US Food and Drug Administration (FDA): an extension of the scientific review time for …

Download PDF
 
Thursday, 02 May 2019

CLINUVEL Newsletter

02 May 2019  Dear patients, shareholders, friends,In this Communiqué we concentrate on CLINUVEL’s programs and US market access for SCENESSE®.As the European season unfolds, we report on the back of quarterly financials (released 30 April) …

Download PDF
 
Wednesday, 24 April 2019

Chair Letter to Shareholders

24 April 2019   Dear All,On a continent where very few biotechnology and pharmaceutical companies have ever succeeded in taking a first-in-class and first-in-line therapy from concept to commercialisation, CLINUVEL has all the makings of becoming …

Download PDF
 
Wednesday, 20 March 2019

CLINUVEL Newsletter – March 2019

20 March 2019  Dear patients, shareholders, friends,In the third Communiqué we are reviewing our EU operations, the impact of Brexit and looking at the year ahead. FDA REVIEWAt the time of print CLINUVEL will find itself …

Download PDF
 
Tuesday, 12 February 2019

CLINUVEL Vitiligo Communiqué II

12 February 2019   In the second Communiqué we look closer at the role of narrowband UVB (NB-UVB) as the only standard of care at present in vitiligo, both the segmental and generalised form of the disease. …

Download PDF
 
Tuesday, 15 January 2019

CLINUVEL Newsletter - January 2019

15 January 2019 Dear patients, shareholders, friends,I wish you all a year in good physical and spiritual health, and a year in which we anticipate further progress of SCENESSE ® (afamelanotide 16mg)1 and CLINUVEL’s other products …

Download PDF